BCL2 and acute myeloid leukemia: Venetoclax (AbbVie, Lake Bluff, Illinois, USA) (formerly ABT-199) is an oral inhibitor of BCL-2 that induced potent and selective apoptosis in AML cell lines and patient samples, as well as in xenograft murine models [5].